MigraineMind research summary
Flunarizine and cinnarizine in the prophylaxis of vestibular migraine and migraine-associated menière's disease: An 8-month retrospective study.
Eur Arch Otorhinolaryngol | 2026
Observational studySummary
This study looked at two treatments for vestibular migraine (VM) and migraine-associated Menière's disease (MAMD). These conditions cause frequent vertigo and can severely affect quality of life. Researchers analyzed data from 402 patients over eight months. They compared flunarizine, given at 10 mg/day, and cinnarizine, given at 75 mg/day. Most patients had experienced these conditions for about ten years. Nearly half had tried other treatments without success. Before treatment, patients had an average of 1.6 vertigo attacks monthly. After eight months, this number dropped significantly to just 0.2 attacks. Additionally, patients reported feeling better overall, and their Dizziness Handicap Inventory scores improved. This suggests that both medications can effectively reduce vertigo attacks and improve life quality for patients suffering from VM and MAMD. Overall, flunarizine and cinnarizine seem promising as preventive treatments for these disorders. Clinical relevance: This study indicates that flunarizine and cinnarizine can significantly reduce vertigo attacks in patients with vestibular migraine and migraine-associated Menière's disease.
Key Learning Points
- Flunarizine and cinnarizine are effective treatments for reducing vertigo attacks in patients with vestibular migraine and migraine-associated Menière's disease.
- Patients experienced a significant decrease in vertigo attacks from an average of 1.6 to 0.2 per month after eight months of treatment.
- Both medications led to improved overall well-being and quality of life for individuals suffering from these conditions.
- Nearly half of the patients had previously tried other treatments without success, highlighting the need for effective options.
- The study involved 402 patients over eight months, providing robust evidence for the effectiveness of these treatments.
Research Informatics
RETROSPECTIVE COHORT STUDY
Flunarizine and cinnarizine reduce vertigo in VM and MAMD.
exposureFlunarizine or cinnarizine treatment
conditionVestibular migraine and migraine-associated Menière's disease
populationPatients with VM or MAMD at vestibular centers
sample Size402
association81.6% response rate with ≥50% reduction
main OutcomeReduction in monthly vertigo attacks
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.